BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34059954)

  • 21. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
    Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
    Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors.
    Patel AV; Chaney KE; Choi K; Largaespada DA; Kumar AR; Ratner N
    EBioMedicine; 2016 Jul; 9():110-119. PubMed ID: 27333032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.
    Cortes-Ciriano I; Steele CD; Piculell K; Al-Ibraheemi A; Eulo V; Bui MM; Chatzipli A; Dickson BC; Borcherding DC; Feber A; Galor A; Hart J; Jones KB; Jordan JT; Kim RH; Lindsay D; Miller C; Nishida Y; Proszek PZ; Serrano J; Sundby RT; Szymanski JJ; Ullrich NJ; Viskochil D; Wang X; Snuderl M; Park PJ; Flanagan AM; Hirbe AC; Pillay N; Miller DT;
    Cancer Discov; 2023 Mar; 13(3):654-671. PubMed ID: 36598417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
    Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
    Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malignant peripheral nerve sheath tumor in children: A clinicopathologic and molecular study with parallels to the adult counterpart.
    Agaram NP; Wexler LH; Chi P; Antonescu CR
    Genes Chromosomes Cancer; 2023 Mar; 62(3):131-138. PubMed ID: 36414547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF mutation, TERT promoter mutation, and HER2 amplification in sporadic or neurofibromatosis-related neurofibromas and malignant peripheral nerve sheath tumors: do these molecules have a signature in malignant transformation?
    Coskun S; Gamsizkan M; Yilmaz I; Yalcinkaya U; Sungur MA; Buyucek S; Onal B
    APMIS; 2020 Sep; 128(9):515-522. PubMed ID: 32580246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
    Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST.
    Chung MH; Aimaier R; Yu Q; Li H; Li Y; Wei C; Gu Y; Wang W; Guo Z; Long M; Li Q; Wang Z
    Cell Oncol (Dordr); 2023 Oct; 46(5):1399-1413. PubMed ID: 37086345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond "Triton": Malignant Peripheral Nerve Sheath Tumors With Complete Heterologous Rhabdomyoblastic Differentiation Mimicking Spindle Cell Rhabdomyosarcoma.
    Hornick JL; Nielsen GP
    Am J Surg Pathol; 2019 Oct; 43(10):1323-1330. PubMed ID: 31107719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
    Spurlock G; Knight SJ; Thomas N; Kiehl TR; Guha A; Upadhyaya M
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1869-80. PubMed ID: 20229272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment and characterization of a recurrent malignant peripheral nerve sheath tumor cell line: RsNF.
    Zhang X; Hu C; Li D; Liu S
    Hum Cell; 2024 Jan; 37(1):345-355. PubMed ID: 37938540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peripheral nerve sheath tumors from patients with neurofibromatosis type 1 do not have the chromosomal translocation t(X;18).
    Liew MA; Coffin CM; Fletcher JA; Hang MT; Tanito K; Niimura M; Viskochil D
    Pediatr Dev Pathol; 2002; 5(2):165-9. PubMed ID: 11910511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth.
    Thomson CS; Pundavela J; Perrino MR; Coover RA; Choi K; Chaney KE; Rizvi TA; Largaespada DA; Ratner N
    Oncogene; 2021 Jun; 40(24):4229-4241. PubMed ID: 34079083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
    Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
    Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
    Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
    Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics.
    Carroll SL
    Am J Pathol; 2016 Mar; 186(3):464-77. PubMed ID: 26740486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.
    Mitchell DK; Burgess B; White EE; Smith AE; Sierra Potchanant EA; Mang H; Hickey BE; Lu Q; Qian S; Bessler W; Li X; Jiang L; Brewster K; Temm C; Horvai A; Albright EA; Fishel ML; Pratilas CA; Angus SP; Clapp DW; Rhodes SD
    Clin Cancer Res; 2024 Mar; 30(5):1038-1053. PubMed ID: 38127282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells.
    Fischer-Huchzermeyer S; Dombrowski A; Hagel C; Mautner VF; Schittenhelm J; Harder A
    Am J Pathol; 2017 Jul; 187(7):1623-1632. PubMed ID: 28502478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.
    Lee W; Teckie S; Wiesner T; Ran L; Prieto Granada CN; Lin M; Zhu S; Cao Z; Liang Y; Sboner A; Tap WD; Fletcher JA; Huberman KH; Qin LX; Viale A; Singer S; Zheng D; Berger MF; Chen Y; Antonescu CR; Chi P
    Nat Genet; 2014 Nov; 46(11):1227-32. PubMed ID: 25240281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating tumor DNA for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Jones J; Cain S; Pesic-Smith J; Choong PFM; Morokoff AP; Drummond KJ; Dabscheck G
    J Neurooncol; 2021 Sep; 154(3):265-274. PubMed ID: 34529228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.